Statistics at a Glance
At a Glance
Estimated New Cases in 2023 35,730
% of All New Cancer Cases 1.8%
Estimated Deaths in 2023 12,590
% of All Cancer Deaths 2.1%
|Year||Rate of New Cases — SEER 8||Rate of New Cases — SEER 12||Death Rate — U.S.||5-Year Relative Survival — SEER 8|
|Observed||Modeled Trend||Observed||Modeled Trend||Observed||Modeled Trend||Observed||Modeled Trend|
New cases come from SEER 12. Deaths come from U.S. Mortality.
All Races, Both Sexes. Rates are Age-Adjusted.
Modeled trend lines were calculated from the underlying rates using the Joinpoint Trend Analysis Software.
The 2020 incidence rate is displayed but not used in the fit of the trend line(s). Impact of COVID on SEER Cancer Incidence 2020 data
New cases are also referred to as incident cases in other publications. Rates of new cases are also referred to as incidence rates.
Rate of New Cases and Deaths per 100,000: The rate of new cases of myeloma was 7.1 per 100,000 men and women per year. The death rate was 3.1 per 100,000 men and women per year. These rates are age-adjusted and based on 2016–2020 cases and deaths.
Lifetime Risk of Developing Cancer: Approximately 0.9 percent of men and women will be diagnosed with myeloma at some point during their lifetime, based on 2017–2019 data.
Prevalence of This Cancer: In 2020, there were an estimated 170,405 people living with myeloma in the United States.
How Many People Survive 5 Years Or More after Being Diagnosed with Myeloma?
Relative survival is an estimate of the percentage of patients who would be expected to survive the effects of their cancer. It excludes the risk of dying from other causes. Because survival statistics are based on large groups of people, they cannot be used to predict exactly what will happen to an individual patient. No two patients are entirely alike, and treatment and responses to treatment can vary greatly.
Based on data from SEER 22 (Excluding IL/MA) 2013–2019. Gray figures represent those who have died from myeloma. Green figures represent those who have survived 5 years or more.
Survival by Stage
Cancer stage at diagnosis, which refers to extent of a cancer in the body, determines treatment options and has a strong influence on the length of survival. In general, if the cancer is found only in the part of the body where it started it is localized (sometimes referred to as stage 1). If it has spread to a different part of the body, the stage is regional or distant. For myeloma, 3.6% are diagnosed at the local stage. The 5-year relative survival for localized myeloma is 79.5%.
|Stage||Percent of Cases||5-Year Relative Survival|
Confined to Primary Site
Spread to Regional Lymph Nodes
Cancer Has Metastasized
SEER 22 (Excluding IL/MA) 2013–2019, All Races, Both Sexes by SEER Combined Summary Stage
New Cases and Deaths
How Common Is This Cancer?
Compared to other cancers, myeloma is relatively rare.
|Rank||Common Types of Cancer||Estimated New
|1.||Breast Cancer (Female)||297,790||43,170|
|3.||Lung and Bronchus Cancer||238,340||127,070|
|5.||Melanoma of the Skin||97,610||7,990|
|7.||Kidney and Renal Pelvis Cancer||81,800||14,890|
Myeloma represents 1.8% of all new cancer cases in the U.S.
In 2023, it is estimated that there will be 35,730 new cases of myeloma and an estimated 12,590 people will die of this disease.
Who Gets This Cancer?
Although a rare disease, myeloma is more common in men than women and among individuals of African American descent. Risk is higher among those with a history of monoclonal gammopathy of undetermined significance (MGUS). The rate of new cases of myeloma was 7.1 per 100,000 men and women per year based on 2016–2020 cases, age-adjusted.
|Non-Hispanic American Indian/Alaska Native||7.9|
|Non-Hispanic Asian/Pacific Islander||5.0|
|Non-Hispanic American Indian/Alaska Native||6.2|
|Non-Hispanic Asian/Pacific Islander||3.2|
SEER 22 2016–2020, Age-Adjusted
|Age Range||Percent of New Cases|
Myeloma is most frequently diagnosed among people aged 65–74.
SEER 22 2016–2020, All Races, Both Sexes
Who Dies From This Cancer?
Myeloma is the fifteenth leading cause of cancer death in the United States. The death rate was 3.1 per 100,000 men and women per year based on 2016–2020 deaths, age-adjusted.
|Non-Hispanic American Indian/Alaska Native||3.9|
|Non-Hispanic Asian/Pacific Islander||1.9|
|Non-Hispanic American Indian/Alaska Native||2.8|
|Non-Hispanic Asian/Pacific Islander||1.2|
U.S. 2016–2020, Age-Adjusted
|Age Range||Percent of Deaths|
The percent of myeloma deaths is highest among people aged 75–84.
U.S. 2016–2020, All Races, Both Sexes
Trends in Rates
Changes Over Time
Keeping track of new cases, deaths, and survival over time (trends) can help scientists understand whether progress is being made and where additional research is needed to address challenges, such as improving screening or finding better treatments.
Using statistical models for analysis, age-adjusted rates for new myeloma cases have not changed significantly over 2010–2019. Age-adjusted death rates have been falling on average 1.3% each year over 2011–2020. 5-year relative survival trends are shown below.
Interactive Statistics with SEER*Explorer
- Create custom graphs and tables
- Download data and images
- Share links to results
SEER*Explorer is an interactive website that provides easy access to a wide range of SEER cancer statistics. It provides detailed statistics for a cancer site by gender, race, calendar year, age, and for a selected number of cancer sites, by stage and histology.Explore Additional Myeloma Statistics
More About This Cancer
Figure: A Myeloma cell (abnormal plasma cell) making M proteins. M proteins are antibodies created by a Myeloma cell.
This type of cancer begins in plasma cells (white blood cells that produce antibodies). It is also called Kahler disease, myelomatosis, and plasma cell myeloma. Plasma cells are white blood cells that make antibodies. Antibodies are part of the immune system. They work with other parts of the immune system to help protect the body from germs and other harmful substances. Each type of plasma cell makes a different antibody.
Myeloma begins when a plasma cell becomes abnormal. The abnormal cell divides to make copies of itself. These abnormal plasma cells are called myeloma cells.
In time, myeloma cells collect in the bone marrow. They may damage the solid part of the bone. When myeloma cells collect in several of your bones, the disease is called "multiple myeloma." This disease may also harm other tissues and organs, such as the kidneys.
Myeloma cells make antibodies called M proteins and other proteins. These proteins can collect in the blood, urine, and organs.
Here are some resources for learning more about myeloma.
- More about risk factors for myeloma
- More about the diagnosis of myeloma
- More about treatment options for myeloma
- More about clinical trials
- More about cancer prevention
All statistics in this report are based on statistics from SEER and the Centers for Disease Control and Prevention's National Center for Health Statistics. Most can be found within SEER*Explorer.
All material in this report is in the public domain and may be reproduced or copied without permission; citation as to source, however, is appreciated.
SEER Cancer Stat Facts: Myeloma. National Cancer Institute. Bethesda, MD, https://seer.cancer.gov/statfacts/html/mulmy.html
These stat facts focus on population statistics that are based on the U.S. population. Because these statistics are based on large groups of people, they cannot be used to predict exactly what will happen to an individual patient. To see tailored statistics, browse SEER*Explorer. To see statistics for a specific state, go to the State Cancer Profiles.
The statistics presented in these stat facts are based on the most recent data available, most of which can be found in SEER*Explorer. In some cases, different year spans may be used.
Estimates of new cases and deaths for 2023 are projections made by the American Cancer Society (ACS), based on earlier reported data.
Cancer is a complex topic. There is a wide range of information available. These stat facts do not address causes, symptoms, diagnosis, treatment, follow-up care, or decision making, although links are provided to information in many of these areas.